Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

EC grants conditional marketing authorisation for ADCETRIS to treat hematological cancers

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

Positive interim data from XBiotech monoclonal antibody Phase II study for type 2 diabetes

New method of testing for West Nile virus

New method of testing for West Nile virus

Ustekinumab success in refractory Crohn’s disease

Ustekinumab success in refractory Crohn’s disease

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

Women respond much better than men to treatment of CFL with rituximab

Women respond much better than men to treatment of CFL with rituximab

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

Leading scientists select first drugs to be evaluated in Alzheimer's clinical study

CRI, MedImmune partner to advance cancer immunotherapy research

CRI, MedImmune partner to advance cancer immunotherapy research

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

New data from Genzyme's AUBAGIO and LEMTRADA clinical trials to be presented at ECTRIMS

Trellis, OMT enter collaboration to generate human antibodies

Trellis, OMT enter collaboration to generate human antibodies

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

CytoDyn announces update on feline immunodeficiency virus therapeutic antibody program

Contract Manufacturing Offering introduced to the biopharmaceutical market by Olympus Biotech

Contract Manufacturing Offering introduced to the biopharmaceutical market by Olympus Biotech

Ranibizumab injections keep those with AMD driving longer

Ranibizumab injections keep those with AMD driving longer

Medistem initiates collaboration with Superview Biotechnology

Medistem initiates collaboration with Superview Biotechnology

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.